We develop novel disease modifying drugs.
Our mission is a simple question we ask ourselves — can we slow down or stop neurodegeneration when treating chronic neurological diseases?
Enterprise Estonia have confirmed their support for an Applied Research Program to develop a small molecule Glial cell line – Derived Neurotrophic Factor (GDNF) mimetics, for the treatment of Parkinson’s Disease and other indications.
We partner with various internationally well-known leading scientists in areas of biomedicine, who have numerous credits to their scientific work.
50+
patents / families
600+
publications
30,000+
citations